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In areas were human visceral leishmaniasis (VL) is endemic, the domestic dog is the main parasite reser-
voir in the infectious cycle of Leishmania infantum. Development of prophylactic strategies to lower the
parasite burden in dogs would reduce sand fly transmission thus lowering the incidence of zoonotic
VL. Here we demonstrate that vaccination of dogs with a recombinant 14 kDa polypeptide of L. infantum
nuclear transport factor 2 (Li-ntf2) mixed with adjuvant BpMPLA-SE resulted in the production of specific
anti-Li-ntf2 IgG antibodies as well as IFN-c release by the animals’ peripheral blood mononuclear cells
stimulated with the antigen. In addition, immunization with this single and small 14 kDa polypeptide
resulted in protracted progression of the infection of the animals after challenging with a high dose of
virulent L. infantum. Five months after challenge the parasite load was lower in the bone marrow of
immunized dogs compared to non-immunized animals. The antibody response to K39, a marker of active
VL, at ten months after challenge was strong and significantly higher in the control dogs than in vacci-
nated animals. At the study termination vaccinated animals showed significantly more liver granulomas
and lymphoid hyperplasia than non-vaccinated animals, which are both histological markers of resis-
tance to infection. Together, these results indicate that the 14 kDa polypeptide is an attractive protective
molecule that can be easily incorporated in a leishmanial polyprotein vaccine candidate to augment/
complement the overall protective efficacy of the final product.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
More than a dozen identified and characterized species of
Leishmania cause diseases in humans ranging from simple self-
healing lesions in cutaneous leishmaniasis (CL) to debilitating
and lethal (if untreated) visceral leishmaniasis (VL) also known
as kala-azar. Transmission of all forms of leishmaniasis occurs nat-
urally by the bites of female sandflies either from infected humans
or from infected animals. Direct transmission of VL by contami-
nated needles in drug-abusers has also been documented [1].
Moreover, effective drugs to treat VL are toxic, non-sterilizing,expensive and difficult to administer. There is no vaccine to
human VL.
In addition to being a human disease VL, is zoonotic infection as
well. Dogs are major reservoirs of the parasite [2,3]. Canine VL
(CVL) is widely distributed in Latin America [4,5] and Mediter-
ranean basin [6,7]. In the USA, the potential for CVL to be a signif-
icant problem has been recently highlighted [8–10].
Two vaccines to CVL are commercially available in Brazil,
Leishmune [11], and Leish-Tec [12] and one in Europe,
CaniLeish [13–15] but these products have not been approved
for human use due to low protection efficacy observed in vacci-
nated dogs as well as because they use saponin-based adjuvant,
which is not suitable for humans. In addition, Leishmune and
CaniLeish are glycoprotein fractions purified from whole extracts
of Leishmania donovani or Leishmania infantum promastigotes
[13,16], therefore have possible complications with standard oper-
ating procedures (SOP) for their manufacture. Consequently, better
vaccines for both CVL and human VL are still in high demand [17].
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identification of VL vaccine candidate molecules that are
abundantly produced in vivo during disease and that are present
in bodily fluids (e.g., urine) of human patients with VL. This
approach led to the identification of several polypeptides of
L. infantum. When tested as vaccine candidates formulated with
the adjuvant monophosphoryl lipid A (MPLA) from Bordetella
pertussis emulsified with squalene (Butantan Institute, São Paulo,
SP, Brazil) one of the polypeptides, L. infantum nuclear transport
factor-2 (Li-ntf2) induced marked parasite burden reduction in
the vaccinated animals compared to control mice [18].
In the present study, using a dog model of the VL we evaluated
the immunogenicity and protective efficacy induced by Li-ntf2
formulated with BpMPLA-SE. The results confirm that this
formulation induces a biased Th1 type of immune response in
these animals and that the anti-K39 antibody response, a
biomarker of disease activity was significantly lower in vaccinated
dogs compared to controls.2. Material and methods
2.1. Animals and veterinary care
Beagle dogs were purchased from Marshall Bio Resources,
North Rose, NY, and housed at the animal facility at The Cummings
School of Veterinary Medicine at Tufts University, Grafton, MA. The
investigation followed all the guidelines of National Institute of
Health for animal experimentation and of the Institutional Animal
Care and Use Committee at Tufts University.
2.2. Parasites
L. infantum (MHOM/BR/00/1669) was kindly supplied by
Dr. Mary E. Wilson (University of Iowa, Iowa City, IA) and was
maintained in vivo in hamsters as previously described [19].
Parasites were isolated from the spleen of infected hamsters and
cultured in Schneider’s medium (Invitrogen, Carlsbad, CA) supple-
mented with 20% FBS (Hyclone, Thermo Scientific, Rockford, IL)
and 2 mM L-glutamine (Gibco-Invitogen, Carlsbad, CA) for
7–10 days at 26 C. Metacyclic promastigotes forms of the parasite
were used for challenge infections of dogs. Challenge was
performed ten days after the last immunization of vaccinated dogs
and control animals of matching sex and age. Dogs were inoculated
intravenously with 107 live, virulent metacyclic L. infantum
promastigotes.
2.3. Immunization and challenge
To confirm in dogs the immunogenicity of the vaccine formula-
tion that we have previously tested in mice [18], 2 groups of 3 dogs
(6 month old, male, Beagle) were immunized subcutaneously three
times (three weeks apart) with either Li ntf2 (50 lg) + BpMPLA-SE
(50 lg), group 1, or with Li ntf2 (50 lg) and no adjuvant, group 2.
BpMPLA-SE (Institute Butantan, São Paulo, Brazil) is an oil-in water
emulsion containing monophosphoryl lipid A (MPLA) derived from
B. pertussis [18].
2.4. IgG ELISA
ELISA testing to detect anti-leishmania K39 antibody was
performed on dogs’ sera obtained before immunization, before
challenge, and every two months thereafter for the14 months of
the study. Briefly, ELISA MaxiSorp plates (Thermo Fisher Scientific)
were coated with 0.1 lg rK39 (InBios International, Inc., Seattle
WA) per well in carbonate buffer overnight following by blockingwith PBS–Tween 0.5%–BSA 5%. Serial twofold dilutions of serum
samples were tested, starting at 1:25. Antibodies to rK39 were
revealed with peroxidase-conjugated anti-IgG secondary antibody
(Abcam Inc, Cambridge, MA) and the substrate 3,30,5,50-tetrame
thylbenzidine (TMB). Optical density was determined at 450 nm.
IgG ELISA was also performed to detect anti-Li-ntf2 antibodies in
the sera of humans with visceral leishmaniasis as well as in dogs
with this disease. Human sera were de-identified samples kindly
provided to us by Dr. Ricardo Fujiwara, Federal University of Minas
Gerais, Belo Horizonte, Brazil. Dog sera were from animals chal-
lenged with L. infantum at The Cummings School of Veterinary
Medicine animal facility.
2.5. Cytokine assay
Three weeks after the last boost peripheral blood mononuclear
cells (PBMCs) were isolated by centrifugation over Histopaque
(Sigma, St. Louis, MO) and suspended in RPMI supplemented with
10% FBS (Hyclone), 100 lg/ml streptomycin, 100U/ml penicillin,
25 mM HEPES, 2 mM L-glutamine, 0.05 mM 2-ME (all Sigma). Cells
(2  105) were added to the wells of a 96-well flat-bottomed cul-
ture microplate (Costar, Lowell, MA) and stimulated at 36 C for
72 h with 5 lg/ml Li-ntf2. Supernatants were collected and assayed
for the presence of IFN-gamma using dog specific ELISA kits
(DuoSet, canine IFN-c, R&D Systems, Minneapolis, MN). Cells
cultured in presence of 5 lg/ml Phytohaemagglutinin (PHA) or
complete medium alone were included as controls.
2.6. Bone marrow sampling
Five and eleven months after challenge dogs were anaes-
thetized and bone marrow (BM) samples were obtained by punc-
turing the trochanteric fossa of proximal femur and dispensed
into citrated tubes. Microscopic observation of Giemsa stained
smears was performed to determine the presence of parasites. If
no parasites were observed after at least 30 min on each of the
slides, the sample was declared negative. The presence of Leishma-
nia parasites was also determined in BM and lymph node (LN) aspi-
rates by parasite growth in culture on biphasic NNN medium. The
tubes were incubated at 25–27 C for one week. A sample was con-
sidered as positive when parasites were observed by microscopic
examination of the culture media.
2.7. Real-time PCR
From each BM sample, white blood cells were isolated by cen-
trifugation over Histopaque (Sigma, St. Louis, MO). DNA was then
extracted by DNeasy Blood and Tissue Kit (Quiagen, USA) accord-
ing to manufactures’ instructions. Two Taq-Man systems were
developed: the Leishmania Taq-Man system and the dog Taq-Man
system. For the Leishmania Taq-Man system the target DNA was
L. infantum DNA polymerase (GeneBank accession number
AF009147), which is a single copy number gene [20]. The amplifi-
cation primers (forward primer, 50-TGTCGCTTGCAGACCAGATG-30;
reverse primer, 50-GCATCGCAGGTGTGAGCAC-30) were designed
to amplify a 90-bp fragment and the fluorogenic probe was (50FA
M-CAGCAACAACTTCGAGCCTGGCACC-30TAMRA). A calibration
curve was prepared using purified DNA from 5  106 Leishmania
parasites. Two copies was the lowest target level reliably quanti-
fied and linearity was maintained up to 2  106 parasites per reac-
tion. For the dog Taq-Man system, the target DNA was intron 12 of
the albumin gene (NCBI Reference Sequence: NC_006595.3). An
intron was chosen in order to amplify only albumin genomic
DNA and thus diagnose the amount of cells present in the sample
[21]. The amplification primers (forward primer 50-ATAGTGT-
TATCTTGGGGGTTCT-30; reverse primer 50-GACGGAAGCTGG-
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the fluorogenic probe was (50FAM-TCTAGCACTGTTATCCTTGTG-
GATGTC-30TAMARA).
2.8. Light microscopy
Random liver samples and one whole popliteal LN were fixed in
10% neutral buffered formalin. Following fixation, liver was
trimmed such that 1 cm2 sections perpendicular to the capsule
were examined. LNs were trimmed at the maximal diameter and
examined in that plane. All tissues were embedded in paraffin,
cut at 5 lm, and stained with hematoxylin and eosin. Liver and
LN serial sections were examined by a veterinary pathologist
(GB) without knowledge of the groups. Lesions were identified,
characterized, and counted or scored to generate quantitative
and semi-quantitative data. For liver sections, granulomas were
counted in 10 random fields magnified 200 times normal and the
average from each dog was calculated. Multiple LN features were
assessed including: Maximum diameter; number of follicles with
germinal centers; degree of sinus histiocytosis; and degree of
cortical/paracortical hyperplasia, which were scored as mild = 3;
moderate = 6; and marked = 9.
2.9. Statistical analysis
Statistical analysis was performed using the SigmaStat 2.0 soft-
ware. Student’s t test was used for comparisons with the level of
significance set at P < 0.05.
3. Results
3.1. Li-ntf2 is immunogenic in humans and dogs
To verify if Li-ntf2 is immunogenic during disease, a pre-
requisite for future vaccine development, de-identified sera
obtained from both VL patients from Brazil and from L. infantum-
infected dogs were tested for the presence of anti-Li-ntf2 antibodies
using ELISA. As control, sera were obtained from healthy Brazilian
subjects and from the naïve dogs before challenge with L. infantum.
Results are illustrated in Fig. 1 and indicate the presence of high
titers of antibody response to Li-ntf2 in both VL patients and
infected dogs. These results, although not surrogates of protection,
confirm that Li-ntf2 is recognized by the host immune systemsFig. 1. Recognition of Li-ntf2 by sera from patients with VL and dogs infected intraveno
endemic area of the disease. (B) Sera from dogs before infection and five months after c
using conventional ELISA. Results represent the average of the ODs obtained from seven sduring infection of these two hosts of L. infantum. Therefore these
findings suggest that vaccination with this leishmanial protein
should induce an immune response that could be boosted during
future exposure of humans and dogs to the parasite.
3.2. Immunogenicity of Li-ntf2 in dogs
In our former studies in mice we vaccinated the animals with
Li-ntf2 formulated with the adjuvant BpMPLA-SE and showed that
this formulation induced IgG2a antibody response and production
of IFN-c by Li-ntf2 specific T cells thus a Th1 biased response [18].
To confirm that this immunization protocol was also effective in
dogs, two groups of six month old, male Beagles were immunized
three times (one month apart) with either Li-ntf2 mixed with
BpMPLA-SE or with Li-ntf2 in saline. All animals were pre-bled
before the immunizations. Throughout the course of these immu-
nizations no local inflammation or systemic symptoms such us,
fever, malaise, or weight loss were observed in any of the immu-
nized animals (not sown). Ten days after the last immunization
the dogs were bled and both sera and PBMCs were obtained. Speci-
fic antibody response was measured by ELISA. PBMCs were cul-
tured in the presence and absence of Li-ntf2 for three days and
IFN-c production was assayed by ELISA in the culture super-
natants. This cytokine is a major surrogate marker of Th1 pheno-
type of immune response. As shown in Fig. 2, dogs immunized
with Li-ntf2 formulated with BpMPLA-SE produced higher titers
of Li-ntf2 specific antibodies and higher concentrations of IFN-c
than those observed in dogs immunized with the same amount
of the protein but with no adjuvant. No antibody response or
IFN-c could be detected in sera and PBMCs obtained from the dogs
before the immunizations (not shown). These results confirm that
the B. pertussis adjuvant formulation not only augments the overall
immunogenicity of the vaccine candidate but also suggests the
development of biased immune response to a Th1 phenotype in
dogs.
3.3. L. infantum amastigotes in BM of vaccinated and control dogs
To begin to investigate the protection potential of the vaccine
candidate one group of 10 dogs (Beagles) were vaccinated three
times (one month apart) with Li-ntf2 emulsified in BpMPLA-SE.
Ten unimmunized Beagle of matching sex, weight and age were
used as control. Thirty days after the last immunization all animalsusly with L. infantum. (A) Sera from patients with VL and control subjects from an
hallenge with L. infantum. Assay for the presence of anti-Li-ntf2 antibody was done
era from patients and controls and four sera from dogs. Bars are the SD of the means.
Fig. 2. Immunogenicity of Li-ntf2 in dogs. Dogs (three per group) were immunized three times (three weeks apart) with either Li-ntf2 (50 lg) + BpMPLA-SE (50 lg), or with Li-
ntf2 (50 lg) with no adjuvant. Blood was obtained 3 weeks after the last immunization and used to assay for antibody response in sera (A) and T cell response (IFN-c
production) in PBMCs (B). Anti Li-ntf2 IgG response was performed in sera diluted at 1/100 and values represent the average of three dogs per group. Ab response was
measured by conventional ELISA. To measure IFN-c production PBMCs were cultured for three days in the presence and absence of 10ug/ml of Li-ntf2. Culture supernatants
were harvested and assayed for the presence of the cytokine by ELISA. (⁄) Significance at P < 0.05 by Student’s t test.
Fig. 3. Microscopic observation (100X) of Giemsa stained BM samples from dogs infected with promastigotes of L. infantum. BM biopsies were harvested under anesthesia
from the dogs’ femur bone five months after challenge with L. infantum. Smears were stained with Giemsa and amastigotes can be clearly seen (white arrow heads). A.
Amastigotes present in one of two out of 10 dogs in vaccinated group. B. Amastigotes present in a macrophage cytoplasm in one of five out of 10 dogs in non-vaccinated
group.
Table 1
Proportion of animals with positive identification (Giemsa staining) of L. infantum
amastigotes in dogs’ BM at five and eleven months after challenge with the parasite.
Group Time after challenge
5 months 11 months
Vaccinated 2/10 5/10
Control 5/10 5/10
4 C. Abeijon et al. / Trials in Vaccinology 5 (2016) 1–7were inoculated intravenously with 107 live, virulent L. infantum
promastigotes. The average weight of dogs from vaccine and con-
trol groups was 10 ± 1 kg at the time of infection. Both groups
gained 2 ± 0.6 kg on average over the 14-month follow up. To esti-
mate parasitic load BM aspirates were conducted at 5 and
11 months after challenge. Microscopic observation of Giemsa
stained BM smears, prepared five months after challenge, demon-
strated the presence of typical Leishmania amastigotes (Fig. 3) from
2 out of 10 vaccinated dogs and 5 out of 10 control animals
(Table 1). However, by the time of the second BM aspiration,
11 month after challenge, Leishmania amastigotes were observed
in half of the samples from each group. This data may suggest that
the vaccine offered a partial protection early on after challenge of
the animals with the parasite.3.4. Detection of L. infantum DNA in BM of vaccinated and control dogs
The parasitic load in the dogs’ BM was also estimated by Real-
Time PCR (RT-PCR) at five and eleven months after the challenge
with L. infantum. The target gene was L. infantum DNA polymerase
and the sensitivity and linear range of the RT-PCR reaction wastested using serial dilutions of parasite DNA extracted from a
known number of promastigotes. Detection reached a level of 2
parasites per reaction with a dynamic range of 106. The dog house-
keeping gene encoding albumin, was also quantified by RT-PCR in
order to perform quantification of BM tissue in each sample.
Five months after the challenge a slight increase in parasite bur-
den was found in the control group of dogs, compared to vacci-
nated animals (Fig. 4). However, the difference was more
pronounced 11 months after challenge when the second BM aspi-
ration was performed. At this time point the parasite burden was
higher in the control group compared to vaccinated group
(Fig. 4). However, this difference was not statistically significant
Fig. 4. Detection of L. infantum DNA in dogs infected with promastigotes of L.
infantum. BM biopsies were harvested under anesthesia from the dogs’ proximal
femur bone five months after challenge with L. infantum. Quantitative real-time
polymerase chain reaction (qPCR) was employed to estimate DNA contents. The L.
infantum target DNA was the DNA polymerase of L. infantum (GeneBank accession
number AF009147), which is a single copy gene. Correlation of the qPCR reaction
with number of Leishmania parasites cells was performed using serial dilutions of
parasite DNA extracted from a known number of promastigotes of L. infantum. Dog
cells’ DNA was estimated based on the animals’ albumin DNA in the same sample.
V: vaccine group, C: control group, mo: Months after challenge with L. infantum.
Bars represent mean + SD.
Fig. 5. Anti K39 antibody response of dogs infected with promastigotes of L.
infantum. Sera were obtained from all dogs before challenge and at two months
interval after challenge of the animals with L. infantum. Anti-K39 antibody response
was measured by conventional ELISA. Sera were diluted at 1/1000 to avoid the high
background noise observed at lower dilutions. Areas represent values changes
through time for results obtained with sera from vaccinated dogs (dark blue shade)
versus results obtained with sera from control animals (light blue shade).
Fig. 6. Histopathology of liver and LNs from dogs with amastigotes of L. infantum in
the BM. Liver granulomas (A) were quantified in 10 random fields at 200x
magnification. Bars represent mean + SEM. Degree of LN hyperplasia (B) was scored
as Mild = 3; Moderate = 6; Severe = 9. A clear trend of differences between the two
groups of animals (Vaccine and Control) were statistically significant in the number
of liver granulomas (P = 0.0238) and close to significant in the LN (P = 0.1667).
Representative photomicrographs from each group are shown magnified 200 (A)
and 100 (B).
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cinated and control group of dogs and the limited sample size.3.5. Anti-rK39 antibody test in sera of vaccinated and control dogs
The presence of antibody response to the conserved 39-amino
acid repeat epitope of L. donovani/L. infantum kinesin (K39) is a
well-accepted and specific marker of active VL in both humans
and dogs [22–33]. To investigate the presence of this marker, sera
were collected from all animals before and after challenge with L.
infantum and tested by ELISA using a rK39 antigen. Anti rK39 anti-
bodies were not present in pre-challenge sera from both groups of
animals. In contrast anti-K39 antibody response was first detected
in both groups of animals four months after challenge and
increased steadily. Fig. 5 illustrates the results and shows that
changes in antibody activity over time observed for sera from vac-
cinated animals throughout the next six months was significantly
less pronounced than that observed for sera from control animals.
These results suggest that the vaccination of dogs with Li-ntf2offered partial protection against challenge of the animals with vir-
ulent L. infantum.
3.6. Histopathology of liver and LNs from vaccinated and control dogs
In canine VL, granulomas are manifestations of innate and adap-
tive responses to Leishmania parasites and are composed of many
types of cells including macrophages, monocytes, dendritic cells,
a variety of lymphocytes, and rarely neutrophils [34]. At study ter-
mination, liver samples and popliteal LNs were examined by vet-
erinary pathologist blinded to the groups. The results are
illustrated in Fig. 6A and clearly show that in dogs with detectable
liver amastigotes, significantly more granulomas were found in
vaccinated dogs compared to unvaccinated animals. These results
support the proposal that vaccination with Li-ntf2 mixed with
BpMPLA-SE induces partial protection against VL.
LN enlargement is another structural manifestation of the
immune response, particularly to chronic infections. LNs were
measured (maximal diameter), follicles with germinal centers
were counted and sinus histiocytosis as well as lymphoid hyper-
plasia (cortical and paracortical) were scored. The only feature
which showed differences among the groups was lymphoid hyper-
plasia (Fig. 6B), which corresponds to lymphocyte accumulation
and proliferation within the LN in response to persistent antigen
stimulation. Maximal hyperplasia was observed in vaccinated
group compared to modest hyperplasia present in unvaccinated
dogs, again, strengthening the findings that suggest that the vac-
cine candidate induces partial protection to VL in dogs.4. Discussion
Typical clinical CVL is characterized by depression, loss of
weight, poor body condition, keratoconjunctivitis, onychosis, skin
ulcers, alopecia, dermatitis, blepharitis, engorgement of patellar
LNs, and splenomegaly [35]. These manifestations usually start to
occur 2–3 months after intravenous challenge with the parasites
[36]. This study was designed to end 14 months after challenge
because parasitological, immunological and tissue pathology data
can be employed to evaluate disease progression at the onset of
6 C. Abeijon et al. / Trials in Vaccinology 5 (2016) 1–7clinical symptoms. Indeed, 2 dogs, one vaccinated and one from the
control group, developed clear clinical signs of visceral leishmani-
asis 12 months after challenge with L. infantum. The animals were
euthanized for humane reasons. Moreover, for vaccine develop-
ment studies, the establishment of an active infection in dogs is
in itself a challenge, as it is clear from the literature that, due to
natural resistance, approximately only one third of dogs naturally
exposed to the parasites commonly found in endemic areas will
progress to active infection [37]. The vaccine candidate tested in
this study, Li-ntf2 mixed with the adjuvant BpMPLA-SE induced a
biased Th1 type immune response and offered protection early
on as evidenced by the lower number of infected dogs detected
by microscopic observation of Giemsa stained BM biopsies.
An alternative way of estimating parasite load in the BM of the
animals is by the detection and quantification of L. infantum DNA
by Real-Time PCR normalized by the number of host nucleated
cells in the sample. The methodology is quantitative and very sen-
sitive compared to conventional microscopic observation of organ
smears. Linearity over six orders of magnitude was attained, as
reported on a study were parasite load in human VL patients was
well correlated to their clinical status [38]. A drawback of this
methodology is that DNA from dead parasites is detected as effi-
ciently as that of live organisms. We believe that the large chal-
lenge dose employed here could be the reason why 5 months
after challenge only a small increase in parasites’ number was
measured in the BM of control dogs compared to vaccinated ani-
mals. At the 11 month time point the parasitic load in the BM of
control dogs had increased by about threefold and that of the vac-
cinated dogs by only twofold, but the difference was not statisti-
cally significant due to the large individual variation found
among vaccinated and control dogs. The variability in the individ-
ual response of dogs to the Leishmania infection was not surprising
because in endemic areas some dogs suffer from severe disease
manifesting multiple signs of VL, while other dogs remain sub clin-
ically infected for years [37].
Further indication that the vaccine partially controlled the
infection was obtained by measuring the antibody response to
K39, a widely accepted marker of active VL. The antibody response
was first detected four months after the challenge and was similar
in both groups of animals. However, from that time-point on the
anti-K39 response was stronger in control animals than that
observed in vaccinated dogs, thus suggesting an anti-CVL protec-
tive efficacy of the formulation Li-ntf2 mixed with the adjuvant
BpMPLA-SE.
Histopathological studies performed at the study termination
showed significantly more granulomas in the liver of vaccinated
dogs. Another structural abnormality, lymphoid hyperplasia,
which is generated in response to persistent antigen stimulation,
was maximal in vaccinated dogs and marginal in the control ani-
mals. These histological responses have been associated resistance
to chronic infection, including CVL [34]. Therefore, these data con-
firm that vaccinated animals mounted a strong immune response
to Li-ntf2 that was partially protective against the intra venous
challenge with a high dose of virulent L. infantum.
The intravenous route of administration is likely to result in
some differences with respect to the establishment of natural
infection, as it bypasses the local dermal immune environment
[39]. In a natural infection, provided by means of sand-fly bites,
the parasite is inoculated along with sand-fly salivary proteins
known to have immune modulating activity [40]. However, artifi-
cial challenge is well accepted in pre-clinical kennel studies in lieu
of the complicated and expensive artificial sand-fly challenge, par-
ticularly in dog studies. Moreover, regardless of the type of chal-
lenge performed in kennel dogs, final validation of the vaccine
candidate needs to be tested in studies where natural infection
occurs in endemic areas of VL.Of note, it is important to highlight that despite the reduced
MW of Li-ntf2 (13.9 kDa) and consequent limited antigenic epitope
repertoire, this molecule induced partial protection in mice [18]
and dogs (this study). In contrast, the successful commercially
available dog vaccines [14,15,12,41–44,16,11,45], which induce
better protection than Li-ntf2, are composed of multiple high
MW proteins ranging from 40 kDa to 100 kDa. One is an amastig-
ote complex protein family [46] and the other two are a broad mix-
ture of native leishmanial promastigote proteins [13,16].
Therefore, because of its small size, Li-ntf2 is an interesting protec-
tive molecule that can be added to expand or to complement the
efficaciousness of existing vaccine formulations.
Indeed, recombinant multi polyprotein vaccines such as Leish
111f and KSAC consisting of multiple antigens, have been shown
to confer better protection against experimental VL in mice and
hamster than single antigen vaccines [47,48], which suggests that
a combination of partially protective vaccine candidates can in the-
ory be constructed to induce better protection. Therefore, Li-ntf2
could be used in combination with other partially protective anti-
gens to generate improved vaccines against canine VL and bring to
a step closer to a much needed human and dog vaccines to VL. We
are currently exploring this possibility with other vaccine candi-
dates that could be complemented with Li-ntf2.
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